Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors

por Calvo, Emiliano, Sessa, Cristiana, Harada, Guilherme, de Miguel, Maria, Kahatt, Carmen, Luepke-Estefan, Xarles Erik, Siguero, Mariano, Fernandez-Teruel, Carlos, Cullell-Young, Martin, Stathis, Anastasios, Drilon, Alexander
Publicado 2022

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study

por Kristeleit, Rebecca, Moreno, Victor, Boni, Valentina, Guerra, Eva M, Kahatt, Carmen, Romero, Ignacio, Calvo, Emiliano, Basté, Neus, López-Vilariño, José A, Siguero, Mariano, Alfaro, Vicente, Zeaiter, Ali, Forster, Martin
Publicado 2021

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

por Kristeleit, Rebecca, Leary, Alexandra, Delord, Jean Pierre, Moreno, Victor, Oaknin, Ana, Castellano, Daniel, Shappiro, Geoffrey I., Fernández, Cristian, Kahatt, Carmen, Alfaro, Vicente, Siguero, Mariano, Rueda, Daniel, Zeaiter, Ali, Awada, Ahmad, Santaballa, Ana, Zaman, Khalil, Sehouli, Jalid, Subbiah, Vivek
Publicado 2023

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

por Subbiah, Vivek, Braña, Irene, Longhi, Alessandra, Boni, Valentina, Delord, Jean-Pierre, Awada, Ahmad, Boudou-Rouquette, Pascaline, Sarantopoulos, John, Shapiro, Geoffrey I., Elias, Anthony, Ratan, Ravin, Fernandez, Cristian, Kahatt, Carmen, Cullell-Young, Martin, Siguero, Mariano, Zeaiter, Ali, Chawla, Sant P.
Publicado 2022